Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Gastrointestinal 1Endocrine 1

Conditions

Pancreatic Neoplasms 1Neoplasm Metastasis 1Lymphoma, Mantle-Cell 1Lymphoma 1Gastro-enteropancreatic neuroendocrine tumor 1Carcinoma, Islet Cell 1

Interventions

Everolimus 4Temozolomide 3Octreotide 2Capecitabine 2Bevacizumab 2temsirolimus 1regorafenib 1pazopanib 1motesanib diphosphate 1folfirinox 1cixutumumab 1batifiban 1Sunitinib 1Sorafenib 1Sirolimus 1Oxaliplatin 1Leucovorin 1Granulocyte Colony-Stimulating Factor 1Fluorouracil 1Filgrastim 1Fentanyl 1Doxorubicin 1Cytokines 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Carcinoma, Islet Cell × Cytokines × Clear all
NCT03042780 2020-11-27

FOLFIRINOX in Metastatic High Grade Gastroenteropancreatic Neuroendocrine Carcinomas

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Terminated
2 enrolled 6 charts
EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Neoplasm Metastasis, Pancreatic Neoplasms, Carcinoma, Islet Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡